Home
CRO Services
CRO Services
Disease Models and Pharmacodynamics

Ophthalmic Disease

CNS Disease

Metabolic Disease

CVD and Other Disease

Regulatory Strategies and Safety Assessment

Regulatory Strategy

Drug Metabolism and Pharmacokinetics

Drug Safety Assessment

Safety Assessment of Medical Devices

Clinical Trials and
Laboratory Services

Clinical Trials

Laboratory Services

Technical platform and instrument Bioanalysis Biomarker Clinical and Molecular Pathology Laboratory
TriApex Vision
Innovative CRO enabling new drug R&D in disease-oriented fields
Disease-Oriented R&D
Disease-Oriented R&D
Ophthalmology

In vivo Ocular Disease Models

Ocular Routes of Administration

Clinical Ophthalmology Examinations

Bioanalysis of Eye Tissues

Ophthalmology Pathology Evaluation

Clinical Service

CNS

Disease Models

Drug Safety Assessment

Clinical Research Services

Project Experience

Metabolic Disease

Disease Models

Service Capacity

Clinical Research Services

Project Experience

Innovation

iPSCs & Organoids Evaluation Department

Cell Biology & Immunology Evaluation Department

TriApex Empowered
To build an international drug evaluation platform for ophthalmic /CNS/ metabolic disease
News&Insight
News&Insight
Top NewsLatest Industry NewsThoughts and InsightsImportant EventsVideo ClassDocument / ManualQ&A
TriApex Vision
Witness the development of industry innovation, share TriApex exclusive insights
Investor
Investor
AnnouncementCorporate GovernancePromotional MaterialsInvestor Contact
TriApex Vision
Building a CRO "bioeconomy" industry ecosystem that meets international standards and is domestically first-class
About us
About us
TriApex ProfileCredibility QualificationSocial ResponsibilityJoin us
鼎泰願景
Dedicated to scientific assessment, enabling transformation of innovation, and improving quality of life
Global
En Cn
×
News & Insight
Location： Home News&Insight
News
TriApex Top News
2023-02-10
TriApex Supported Argo Biopharma in Approval of IND of the Second siRNA Drug in Australia.
2023-01-19
TriApex Supported Exegenesis Bio in Approval of IND of EXG102-031 Intraocular Injection by FDA
2022-11-04
TriApex Supported Tavotek Biotherapeutics in Approval of IND of Multi-specific Antibody TAVO412 by FDA
 Browse more news
Latest Industry News
2022-11-28
Online Training tomorrow: CDE will organize the online training of ICH Q8(R2)-Q12 Guidelines
2022-11-25
Six guidelines were issued! CDE released 6 guidelines, including guidelines for bioequivalence research of several generic drugs, and guidelines for clinical research and development of antitumor photodynamic therapy drugs.
2022-10-19
CDE training | Online training of serial ICH guidelines for pharmacovigilance
 Browse more policy
Our resources
Research tools
Microscope
Reagent bottle
Petri dish
q&a
What is TriApex's business and industrial layout? What are the advantages of TriApex in regulatory certification and compliance? What are the customer groups of TriApex and what product areas are involved?
View more
Important Events
Browse more
TriApex will be attending SOT 63rd annual meeting in March, looking forward to seeing you there!
The 10th National Toxicology Congress of CST (10th NTCCST) will be held on April in Zhuhai.
2023-02-08
The 2nd China-Lingang Biomedical Innovation and Development Summit 2022 Frontier Drug Research and Development theme Forum was successfully concluded
2022-12-05
Lichuan Yang , CEO of KBI from TriApex, was invited to attend the ICNS 2022 Focus Forum and give a keynote speech
2022-11-07
Video Class
Browse more
Bioanalytical Strategies in Immune Cell Therapies
Bioanalytical Strategies in Immune Cell Therapies
Clinical Study of AAV Gene Therapies
Clinical Study of AAV Gene Therapies
Pharmacokinetic and Pharmacodynamic Method Selecting and Development for CAR-T Cell Therapies
Researcher of TriApex —— Zaichao Zheng
Thoughts and Insights
Browse more
Analysis of the influence of different tear collection, processing and sampling methods on the results
2023-01-05
Read more
Review of CDE on the ICH S1/S1B(R1) Testing for Carcinogenicity of Pharmaceuticals and interpretation by FDA experts of the latest guidelines for reducing the use of carcinogenic laboratory animals
2022-11-23
Read more
ADME characteristics and PK-PD models of GalNAc-siRNAs
2022-11-23
Read more
Subscribe to our newsletter to keep up to date with the latest newsSubscribe Now >>
Online Message×
Click switch
An innovative CRO dedicated to providing disease-oriented one-stop solutions to enable the R&D for global pharmaceutical enterprises and research institutions.
CRO Services

Disease Models and Pharmacodynamics

Regulatory Strategies and Safety Assessment

Clinical Trials and Laboratory Services

Disease-Oriented R&D

Ophthalmology

CNS

Metabolic Disease

Innovation

News&Insight

Top News

Latest Industry News

Thoughts and Insights

Important Events

Video Class

Document / Manual

Q&A

About us

TriApex Profile

Credibility Qualification

Social Responsibility

Join us

Tel：+86(025) 5819-6588

Email：BD@tri-apex.com

Address：9 Xinglong Road, Jiangbei New Area, Nanjing, China

Members of TriApex
TriApex Nanjing
TriApex Nanjing Kunming Biomed (KBI) TriApex Med TriApex Biotechnology Harborside
Official WeChat account
Official video account
Copyright©TriApex Laboratories Co., Ltd. 技術支持：集錦科技